SPA
ALLO icon

Sherbrooke Park Advisers’s Allogene Therapeutics ALLO Stock Holding History

Sherbrooke Park Advisers’s Portfolio ALLO Stock Details ALLO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-107,398
Closed -$480K – 884
2024
Q1 		$480K Buy
+107,398
New +$448K 0.09% 374

Other funds holding ALLO

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
TGA
TPG GP A Fort Worth, Texas $3.68B AUM 14.99% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Sherbrooke Park Advisers's ALLO Position: Q2 2024 in Review

Sherbrooke Park Advisers sold out of Allogene Therapeutics (ALLO) in Q2 2024, closing a stake of 107,398 shares — an estimated $480K sold.

Sherbrooke Park Advisers first reported a position in ALLO in Q1 2024 and held it in 1 quarter. The position peaked at $480K in Q1 2024. 174 funds tracked by Wall St. Rank hold ALLO as of Q2 2024.

  • Sherbrooke Park Advisers reported no remaining Allogene Therapeutics position as of Q2 2024 after selling out during the quarter.
  • Sherbrooke Park Advisers sold 107,398 Allogene Therapeutics shares in Q2 2024, an estimated $480K.
  • Sherbrooke Park Advisers first reported a position in Allogene Therapeutics in Q1 2024 and held it in 1 quarter.
  • Sherbrooke Park Advisers's Allogene Therapeutics position peaked at $480K in Q1 2024.
  • 174 funds tracked by Wall St. Rank held Allogene Therapeutics as of Q2 2024.

Based on Sherbrooke Park Advisers's 13F filing for Q2 2024, filed 14 Aug 2024.